272 related articles for article (PubMed ID: 27078747)
1. An antithrombin replacement strategy during asparaginase therapy for acute lymphoblastic leukemia is associated with a reduction in thrombotic events.
Farrell K; Fyfe A; Allan J; Tait RC; Leach M
Leuk Lymphoma; 2016 Nov; 57(11):2568-74. PubMed ID: 27078747
[TBL] [Abstract][Full Text] [Related]
2. Changes in antithrombin and fibrinogen levels during induction chemotherapy with L-asparaginase in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma. Use of supportive coagulation therapy and clinical outcome: the CAPELAL study.
Hunault-Berger M; Chevallier P; Delain M; Bulabois CE; Bologna S; Bernard M; Lafon I; Cornillon J; Maakaroun A; Tizon A; Padrazzi B; Ifrah N; Gruel Y;
Haematologica; 2008 Oct; 93(10):1488-94. PubMed ID: 18728028
[TBL] [Abstract][Full Text] [Related]
3. Cerebral venous thrombosis in adult patients with acute lymphoblastic leukemia or lymphoblastic lymphoma during induction chemotherapy with l-asparaginase: The GRAALL experience.
Couturier MA; Huguet F; Chevallier P; Suarez F; Thomas X; Escoffre-Barbe M; Cacheux V; Pignon JM; Bonmati C; Sanhes L; Bories P; Daguindau E; Dorvaux V; Reman O; Frayfer J; Orvain C; Lhéritier V; Ifrah N; Dombret H; Hunault-Berger M; Tanguy-Schmidt A
Am J Hematol; 2015 Nov; 90(11):986-91. PubMed ID: 26214580
[TBL] [Abstract][Full Text] [Related]
4. Thrombosis associated with L-asparaginase therapy and low fibrinogen levels in adult acute lymphoblastic leukemia.
Beinart G; Damon L
Am J Hematol; 2004 Dec; 77(4):331-5. PubMed ID: 15551293
[TBL] [Abstract][Full Text] [Related]
5. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study.
Mitchell LG; Andrew M; Hanna K; Abshire T; Halton J; Anderson R; Cherrick I; Desai S; Mahoney D; McCuster P; Wu J; Dahl G; Chait P; de Veber G; Lee KJ; Mikulis D; Ginsberg J; Way C;
Cancer; 2003 Jan; 97(2):508-16. PubMed ID: 12518376
[TBL] [Abstract][Full Text] [Related]
6. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving l-asparaginase for acute lymphoblastic leukemia. Results of the PAARKA study.
Mitchell L; Andrew M; Hanna K; Abshire T; Halton J; Wu J; Anderson R; Cherrick I; Desai S; Mahoney D; McCusker P; Chait P; Abdolell M; de Veber G; Mikulis D
Thromb Haemost; 2003 Aug; 90(2):235-44. PubMed ID: 12888870
[TBL] [Abstract][Full Text] [Related]
7. L-Asparaginase lowers plasma antithrombin and mannan-binding-lectin levels: Impact on thrombotic and infectious events in children with acute lymphoblastic leukemia.
Merlen C; Bonnefoy A; Wagner E; Dedeken L; Leclerc JM; Laverdière C; Rivard GE
Pediatr Blood Cancer; 2015 Aug; 62(8):1381-7. PubMed ID: 25820776
[TBL] [Abstract][Full Text] [Related]
8. Incidence of asparaginase-related hepatotoxicity, pancreatitis, and thrombotic events in adults with acute lymphoblastic leukemia treated with a pediatric-inspired regimen.
Christ TN; Stock W; Knoebel RW
J Oncol Pharm Pract; 2018 Jun; 24(4):299-308. PubMed ID: 28355969
[TBL] [Abstract][Full Text] [Related]
9. Thromboembolism in adults with acute lymphoblastic leukemia during induction with L-asparaginase-containing multi-agent regimens: incidence, risk factors, and possible role of antithrombin.
Elliott MA; Wolf RC; Hook CC; Pruthi RK; Heit JA; Letendre LL; Tefferi A; Kaufmann SH; Mesa RA; Litzow MR
Leuk Lymphoma; 2004 Aug; 45(8):1545-9. PubMed ID: 15370205
[TBL] [Abstract][Full Text] [Related]
10. Antithrombin supplementation did not impact the incidence of pegylated asparaginase-induced venous thromboembolism in adults with acute lymphoblastic leukemia.
Chen J; Ngo D; Aldoss I; Shayani S; Tsai NC; Pullarkat V
Leuk Lymphoma; 2019 May; 60(5):1187-1192. PubMed ID: 30322332
[TBL] [Abstract][Full Text] [Related]
11. Conservative treatment of L-asparaginase-associated lipid abnormalities in children with acute lymphoblastic leukemia.
Cohen H; Bielorai B; Harats D; Toren A; Pinhas-Hamiel O
Pediatr Blood Cancer; 2010 May; 54(5):703-6. PubMed ID: 20063421
[TBL] [Abstract][Full Text] [Related]
12. Thrombotic effects of asparaginase in two acute lymphoblastic leukemia protocols (NOPHO ALL-1992 versus NOPHO ALL-2000): a single-institution study.
Ruud E; Holmstrøm H; de Lange C; Natvig S; Albertsen BK; Wesenberg F
Pediatr Hematol Oncol; 2006; 23(3):207-16. PubMed ID: 16517537
[TBL] [Abstract][Full Text] [Related]
13. Thrombosis related to the use of L-asparaginase in adults with acute lymphoblastic leukemia: a need to consider coagulation monitoring and clotting factor replacement.
Alberts SR; Bretscher M; Wiltsie JC; O'Neill BP; Mokri B; Witzig TE
Leuk Lymphoma; 1999 Feb; 32(5-6):489-96. PubMed ID: 10048421
[TBL] [Abstract][Full Text] [Related]
14. FDA drug approval summary: pegaspargase (oncaspar) for the first-line treatment of children with acute lymphoblastic leukemia (ALL).
Dinndorf PA; Gootenberg J; Cohen MH; Keegan P; Pazdur R
Oncologist; 2007 Aug; 12(8):991-8. PubMed ID: 17766659
[TBL] [Abstract][Full Text] [Related]
15. Use of L-asparaginase in acute lymphoblastic leukemia: recommendations of the Polish Adult Leukemia Group.
Piatkowska-Jakubas B; Krawczyk-Kuliś M; Giebel S; Adamczyk-Cioch M; Czyz A; Lech Marańda E; Paluszewska M; Pałynyczko G; Piszcz J; Hołowiecki J;
Pol Arch Med Wewn; 2008 Nov; 118(11):664-9. PubMed ID: 19140571
[TBL] [Abstract][Full Text] [Related]
16. [Cerebral sinovenous thrombosis and acquired antithrombin, protein C and S deficiency during chemotherapy in a young man: report of a case].
Munoz VT; Triffet A; Cauchie P; Brohée D
Rev Med Brux; 2008; 29(6):535-9. PubMed ID: 19202708
[TBL] [Abstract][Full Text] [Related]
17. L-asparaginase and venous thromboembolism in acute lymphocytic leukemia.
Goyal G; Bhatt VR
Future Oncol; 2015; 11(17):2459-70. PubMed ID: 26274336
[TBL] [Abstract][Full Text] [Related]
18. L-asparaginase in acute lymphoblastic leukemia treatment: the role of human antithrombin III concentrates in regulating the prothrombotic state induced by therapy.
Pogliani EM; Parma M; Baragetti I; Mostarda G; Rivolta F; Maffé P; Corneo G
Acta Haematol; 1995; 93(1):5-8. PubMed ID: 7725851
[TBL] [Abstract][Full Text] [Related]
19. Incidence of thrombotic complications in adult patients with acute lymphoblastic leukaemia receiving L-asparaginase during induction therapy: a retrospective study. The GIMEMA Group.
Gugliotta L; Mazzucconi MG; Leone G; Mattioli-Belmonte M; Defazio D; Annino L; Tura S; Mandelli F
Eur J Haematol; 1992 Aug; 49(2):63-6. PubMed ID: 1397242
[TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity reactions to L-asparaginase do not impact on the remission duration of adults with acute lymphoblastic leukemia.
Larson RA; Fretzin MH; Dodge RK; Schiffer CA
Leukemia; 1998 May; 12(5):660-5. PubMed ID: 9593262
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]